Clinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, Sichuan Province, P.R. China.
Key laboratory of transfusion adverse reactions, CAMS, Chengdu, Sichuan Province, P.R. China.
J Clin Apher. 2021 Jun;36(3):429-436. doi: 10.1002/jca.21882. Epub 2021 Feb 15.
Since early 2020, convalescent plasma has been widely used for treating coronavirus disease 2019 (COVID-19). There is limited information regarding donor tolerability of convalescent plasma donation. In this study, we evaluated the short-term donor tolerability of convalescent plasma donation.
A prospective study of 309 convalescent plasma donation related adverse events were conducted at Wuhan Blood Center of China, from February 12 to April 1, 2020. Additionally, up to 28-day post-donation follow-ups were performed on the donors.
Sixteen (5.2%) adverse events were reported in 309 donations. All of these were mild vasovagal without loss of consciousness. The frequency of adverse reactions was higher in donors with a per donation volume of >8 mL/kg body weight or ≥ 600 mL, <100 mm Hg in pre-donation systolic blood pressure, or less than 28 days from the onset of COVID-19 symptoms. There was no correlation to donation history, weight, sex, ABO blood type, pre-donation diastolic blood pressure, pulse, or hemoglobin.
The donation of convalescent plasma is generally safe. Mitigation of risk factors associated with adverse events can further enhance donor tolerability of convalescent plasma donation.
自 2020 年初以来，恢复期血浆已被广泛用于治疗 2019 年冠状病毒病（COVID-19）。关于供体接受恢复期血浆捐献的耐受性的信息有限。在这项研究中，我们评估了恢复期血浆捐献的短期供体耐受性。
2020 年 2 月 12 日至 4 月 1 日，在中国武汉血液中心对 309 例与恢复期血浆捐献相关的不良事件进行了前瞻性研究。此外，对供体进行了长达 28 天的捐献后随访。
在 309 次捐献中报告了 16 次（5.2%）不良事件。所有这些都是轻度血管迷走神经性的，没有失去意识。在每次捐献量>8 mL/kg 体重或≥600 mL、捐献前收缩压<100 mmHg 或距 COVID-19 症状发作不到 28 天的供体中，不良反应的频率更高。与献血史、体重、性别、ABO 血型、捐献前舒张压、脉搏或血红蛋白无关。
恢复期血浆的捐献通常是安全的。减轻与不良事件相关的风险因素可以进一步提高恢复期血浆捐献的供体耐受性。
